TransCode Therapeutics, Inc.
RNAZ
$10.26
$0.848.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.66M | 951.70K | 1.45M | 938.00K | 2.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.22M | 3.17M | 5.09M | 2.17M | 5.11M |
| Operating Income | -4.22M | -3.17M | -5.09M | -2.17M | -5.11M |
| Income Before Tax | -4.28M | -12.09M | -5.92M | -2.32M | -5.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.28M | -12.09M | -5.92M | -2.32M | -5.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.28M | -12.09M | -5.92M | -2.32M | -5.19M |
| EBIT | -4.22M | -3.17M | -5.09M | -2.17M | -5.11M |
| EBITDA | -4.21M | -3.16M | -5.08M | -2.15M | -5.08M |
| EPS Basic | -5.13 | -70.16 | -271.57 | -146.06 | -- |
| Normalized Basic EPS | -3.21 | -43.85 | -169.75 | -91.29 | -- |
| EPS Diluted | -5.13 | -70.16 | -271.57 | -146.06 | -- |
| Normalized Diluted EPS | -3.21 | -43.85 | -169.75 | -91.29 | -- |
| Average Basic Shares Outstanding | 833.70K | 172.30K | 21.80K | 15.90K | -- |
| Average Diluted Shares Outstanding | 833.70K | 172.30K | 21.80K | 15.90K | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |